GLP 1 cost effectiveness holds in the Military Health System at $250 a month
A Walter Reed model presented at ObesityWeek found tirzepatide and semaglutide cost effective at a $250 monthly drug cost, with tirzepatide near the point of saving money. TRICARE For Life members still have no weight loss cover.
Who feels it
-
Payers
Rethink
Shows the same drugs look cost effective at a $250 monthly cost, far below typical private net prices.
-
Patients
Worth knowing
No coverage rule changes; TRICARE For Life members still have no weight loss drug cover.
-
Prescribers
Worth knowing
Adds a cost argument for treating obesity with related illness inside military care.
-
Sellers
Worth knowing
Tirzepatide sits just above the price at which the model says it saves money for younger adults.
-
Pharmacies
Passes by
—
A model presented at ObesityWeek finds GLP 1 cost effectiveness is strong in the US Military Health System when the drugs are priced at $250 a month. At that figure, tirzepatide and both forms of semaglutide came in far below the usual $100,000 per quality adjusted life year threshold for adults with obesity and a related illness. The analysis, led by a Walter Reed physician and reported by Healio on November 15, also names the yearly prices at which each drug would save money outright.
What the Military Health System model tested
Taylor Neuman, who leads the weight management and metabolic health service at Walter Reed National Military Medical Center, presented the work at the meeting in National Harbor, Maryland. The system serves more than 9 million people, counting active duty troops and their families, Healio reported. Neuman said obesity among active duty troops rose from 8 percent in 2002 to 23 percent in 2023, and that across the whole system 42 percent are overweight and 26 percent have obesity. Use of obesity drugs climbed from 0.56 percent of people in 2018 to 2022 to 5.5 percent in 2023 to 2024. Because tirzepatide and semaglutide account for most of that use, the team set out to test them against the prices the system actually pays.
The researchers used a published Institute for Clinical and Economic Review model that follows adults with overweight or obesity and at least one related illness, but no type 2 diabetes. It simulates new diabetes, heart disease, kidney failure, cirrhosis, joint replacement and sleep apnea over time. Three products were compared with lifestyle changes alone: tirzepatide injections, semaglutide injections and the oral semaglutide tablet sold as the Wegovy pill. Each was given a drug cost of $3,000 a year, or $250 a month, with future costs discounted at 3 percent a year. The eligible group held 354,978 adults aged 18 to 64, with an average age of 45, and 17,688 adults aged 65 to 75.
GLP 1 cost effectiveness by drug and age
Every product cleared the threshold in both age groups, with tirzepatide strongest. In adults under 65, tirzepatide cost $698 for each quality adjusted life year gained, a figure Neuman called the result that jumps out most. Injectable semaglutide came in at $10,838 and the tablet at $14,118. Costs per year of healthy life were higher in the older group, at $15,742 for tirzepatide, $25,770 for injectable semaglutide and $35,873 for the tablet, but still far under $100,000. The sensitivity checks showed the tirzepatide result for younger adults turned mostly on the cost of treating diabetes, how often diabetes develops and starting body mass index. The newer higher strength semaglutide injection was not part of the model.
In adults under 65, tirzepatide cost $698 for each quality adjusted life year gained, a figure Neuman called the result that jumps out most.
The team also ran a break even test: the yearly price at which each drug becomes fully dominant, meaning it both improves health and lowers total cost. For tirzepatide that point was $2,942.60 a year or less in the younger group, only a little under the $3,000 used in the model. Neuman said tirzepatide would need only a fairly small price cut to reach it. The thresholds for semaglutide were lower, and all of them fell for older adults, whose shorter time horizon leaves less room for savings to build. The table below lists both sets of figures as Healio reported them. None of these numbers is a price any patient pays, and the system does not publish its contract terms.
| Drug | Cost per QALY age 18 to 64 | Cost per QALY age 65 to 75 | Saves money below age 18 to 64 | Saves money below age 65 to 75 |
|---|---|---|---|---|
| Tirzepatide injection | $698 | $15,742 | $2,942.60 a year | $1,906.10 a year |
| Semaglutide injection | $10,838 | $25,770 | $2,299.90 a year | $1,577.40 a year |
| Semaglutide tablet | $14,118 | $35,873 | $2,183.70 a year | $1,312.50 a year |
TRICARE coverage after the 2025 cut
The model lands in a system that has already narrowed cover. TRICARE stopped paying for weight loss drugs such as Wegovy and Zepbound for TRICARE For Life members, the Medicare eligible retirees and their families, on August 31, 2025, according to Military Times. The Defense Health Agency said that coverage had not been authorized under federal law for that group. TRICARE Prime, Select and the premium based plans kept weight loss cover, with prior authorization, clinical criteria and a network prescriber. GLP 1 drugs prescribed for type 2 diabetes stayed covered for people with that diagnosis. So the 65 to 75 group in the model includes many people who, under current rules, cannot get a weight loss prescription paid by TRICARE at all.
Neuman framed the work as an argument to look past the yearly pharmacy bill. He said the system's figures look more favourable than other published studies and that he hopes coverage decisions will weigh longer term benefits and possible savings, according to the Healio report. That pitch runs against the trend in employer plans, where studies found no savings large enough to cover the drugs. The difference is largely the price. A $250 monthly drug cost is well below the $449 flat price Lilly has published for employers, and closer to what public programs have negotiated, such as the $274 Medicare semaglutide price set for 2027.
Why the price assumption decides the answer
GLP 1 cost effectiveness models are only as good as their inputs, and this one depends heavily on the drug cost. The presentation was a conference talk, not a peer reviewed paper, and Healio did not report how long patients were assumed to stay on treatment or what happens to the benefits when they stop. Real world use often falls well short of trial adherence, and weight regain after stopping is common. The model also excluded people who already have type 2 diabetes, a group in which medical savings tend to arrive sooner, according to a separate CVS Health analysis this month. For a reader comparing studies, the key point is that the same drugs can look cost saving in one system and cost adding in another, mostly because of what each system pays.
For military families the practical questions are coverage rules, not cost per QALY. Prime and Select members can still get weight loss GLP 1 drugs paid when they meet the criteria, while TRICARE For Life members cannot. The study does not change any rule, and the Defense Health Agency has not said it will revisit the 2025 cut. It does give advocates and lawmakers a figure to cite when they argue that a public system paying a low negotiated price gets value from these drugs. Other public plans and state budgets will read it the same way: the deciding number is the net price, not the drug itself.
Conclusion
The Walter Reed analysis shows GLP 1 cost effectiveness in the Military Health System at a $250 monthly price, with tirzepatide close to saving money outright. It is a model presented at a conference, built on a negotiated price that private plans rarely match. It changes no TRICARE rule, and TRICARE For Life members still lack weight loss cover. This is research and policy reporting, not medical advice.
Source Neuman T, et al. Oral-015, ObesityWeek, November 14 to 17, 2026, National Harbor, as reported by Healio; Military Times on the 2025 TRICARE For Life change
Sources
Spotted an error? Tell us through the contact form; we follow the corrections policy.